73 results on '"Jacobson, Caron A."'
Search Results
2. Impact of Complete Response (CR) on Long-Term Survival Among Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL)
3. Real-World Tisagenlecleucel Outcomes in Richter-Transformed Chronic Lymphocytic Leukemia: A Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis
4. Outcomes in Patients (pts) with R/R Large B-Cell Lymphoma (LBCL) Who Received Nonconforming Product (NCP) to Commercial Release of Lisocabtagene Maraleucel (liso-cel) in the United States (US)
5. Durable Efficacy and Manageable Safety in Patients Age ≥75 Years with Relapsed/Refractory Large B-Cell Lymphoma Treated with Tisagenlecleucel in the Real-World Setting
6. A comparison of 3-year follow-up of ZUMA-5 (axicabtagene ciloleucel) with SCHOLAR-5 in relapsed/refractory follicular lymphoma
7. Effective sequencing of chimeric antigen receptor T-cell therapy in the treatment of LBCL in 2023
8. CAR T Cells: Past Successes, Current Limitations, and Future Opportunities
9. CAR T-Cell
10. Real-world outcomes with CAR T-cell therapies in large B-cell lymphoma: a systematic review and meta-analysis
11. POSTER: ABCL-004 Salvage Radiotherapy in Relapsed/Refractory Large B-Cell Lymphoma After CAR T-Cell Therapy Failure
12. ABCL-004 Salvage Radiotherapy in Relapsed/Refractory Large B-Cell Lymphoma After CAR T-Cell Therapy Failure
13. Chimeric Antigen Receptor T-Cells in Indolent Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia
14. Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Immunogenicity among Chimeric Antigen Receptor T Cell Therapy Recipients
15. Outcomes of Subsequent Anti-Lymphoma Therapies in Patients (Pts) with Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel (Axi-Cel) or Standard of Care (SOC) in the Second-Line (2L) Zuma-7 Study
16. Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/ Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of Zuma-1 Cohort 6
17. Interim Analysis of a Phase II Study of Administered Fresh Bispecific Anti-CD20/Anti-CD19 CAR T-Cell Therapy: Zamtocabtagene Autoleucel (zamto-cel) for Relapsed/ Refractory (R/R) DLBCL (DALY II USA NCT04792489)
18. 3-Year Follow-up Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)
19. Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States
20. P-006: Real world experience of patients treated with idecabtagene vicleucel: a BCMA-directed chimeric antigen receptor T-cell therapy for multiple myeloma
21. Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies
22. Long-Term (5 Year) Overall Survival in Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B-Cell Lymphoma (LBCL)
23. Primary Analysis of Zuma-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care (SOC) Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma
24. Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/ Refractory Large B-Cell Lymphoma (R/R LBCL): 1-Year Follow-up of Zuma-1 Cohort 6 (C6)
25. Cost-Effectiveness of CD19 Chimeric Antigen Receptor T Cell Therapy Versus Autologous Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma in First Relapse
26. Allogeneic Hematopoietic Cell Transplantation for Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) after Chimeric Antigen Receptor T-Cell Therapy Failure
27. Safety, Efficacy, and Outcomes of CD19 CAR T Cell Therapy in 20 Patients with Solid Organ Transplant (SOT)-Related Post-Transplant Lymphoproliferative Disorder (PTLD) in the Real World Setting
28. Long-Term Follow-up Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)
29. Pre and Post-Treatment CD27+ T Cells Track with Clinical Efficacy of Axi-Cel in DLBCL Patients
30. Safety and Preliminary Efficacy, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Axicabtagene Ciloleucel in Combination with Utomilumab in Adults with Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-11, NCT03704298)
31. Effectiveness and Safety of Axicabtagene-Ciloleucel and Tisagenlecleucel for Large B-Cell Lymphoma (LBCL) in the Real-World Setting: A Systematic Review and Meta-Analysis
32. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
33. Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma
34. Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study
35. CAR T-cell Therapy in Indolent Lymphoma
36. Safety and Efficacy of a DNA Oligonucleotide Therapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
37. Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing Analysis
38. Retreatment with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL) in Zuma-5
39. Health Care Utilization and End of Life (EOL) Outcomes in Patients Receiving CAR T-Cell Therapy
40. Prophylactic Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL)
41. Impact of COVID-19 Pandemic on Hematopoietic Stem Cell Transplantation (HSCT) and Immune Effector Cell (IEC) Therapies: A Large US Cancer Center Experience
42. Primary Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)
43. Long-Term Survival and Gradual Recovery of B Cells in Patients (Pts) with Refractory Large B Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel (Axi-Cel)
44. Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleucel (Axi-Cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access (EA) and Commercial out-of-Specification (OOS) Product
45. One-Year Follow-up of ZUMA-2, the Multicenter, Registrational Study of KTE-X19 in Patients (Pts) with Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL)
46. Pharmacological Profile and Clinical Outcomes of KTE-X19 By Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Exposure or Mantle Cell Lymphoma (MCL) Morphology in Patients (Pts) with Relapsed/Refractory (R/R) MCL in the ZUMA-2 Trial
47. ABCL-122: Retreatment (reTx) of Patients with Refractory Large B Cell Lymphoma with Axicabtagene Ciloleucel (Axi-Cel) in ZUMA-1
48. IBCL-124: Interim Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (R/R iNHL)
49. Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma
50. Chimeric antigen receptor (CAR) T-cells on the march: from diffuse large B-cell lymphoma to mantle cell lymphoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.